Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1999 Jan;80(1):36–41. doi: 10.1136/adc.80.1.36

Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections

T Sas 1, S Keizer-Schrama 1, T Stijnen 1, A van Teunenbroek 1, A Hokken-Koelega 1, J Waelkens 1, G Massa 1, T Vulsma 1, W Gerver 1, H Reeser 1, H E D-v de Waal 1, M Jansen 1, S Drop 1, D the 1
PMCID: PMC1717808  PMID: 10325756

Abstract

OBJECTIVES—To study final height in girls with Turner's syndrome treated with once or twice daily injections of growth hormone (GH) in combination with low dose ethinyl oestradiol.
DESIGN—Until final height was reached, the effect of fractionated subcutaneous injections given twice daily was compared with once daily injections of a total GH dose of 6 IU/m2/day. Twice daily injections were given as one third in the morning and two thirds at bedtime. All girls concurrently received low dose oestradiol (0.05 µg ethinyl oestradiol/kg/day, increased to 0.10 µg/kg/day after 2.25years).
PATIENTS—Nineteen girls with Turner's syndrome aged ⩾ 11 years (mean (SD) 13.6 (1.7) years).
MEASUREMENTS—To determine final height gain, we assessed the difference between the attained final height and the final height predictions at the start of treatment. These final height predictions were calculated using the Bayley-Pinneau (BP) prediction method, the modified projected adult height (mPAH), the modified index of potential height (mIPHRUS), and the Turner's specific prediction method (PTSRUS).
RESULTS—The gain in final height (mean (SD)) was not significantly different between the once daily and the twice daily regimens (7.6(2.3) v 5.1 (3.2) cm). All girls exceeded their adult height prediction (range, 1.6-12.3 cm). Thirteen of the 19 girls had a final height gain > 5.0 cm. Mean (SD) attained final height was 155.5 (5.4) cm. A "younger bone age" at baseline and a higher increase in height standard deviation score for chronological age (Dutch-Swedish-Danish references) in the first year of GH treatment predicted a higher final height gain after GH treatment.
CONCLUSIONS—Division of the total daily GH dose (6 IU/m2/day) into two thirds in the evening and one third in the morning is not advantageous over the once daily GH regimen with respect to final height gain. Treatment with a GH dose of 6 IU/m2/day in combination with low dose oestrogens can result in a significant increase in adult height in girls with Turner's syndrome, even if they start GH treatment at a relatively late age.



Full Text

The Full Text of this article is available as a PDF (143.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albertsson-Wikland K., Rosberg S. Analyses of 24-hour growth hormone profiles in children: relation to growth. J Clin Endocrinol Metab. 1988 Sep;67(3):493–500. doi: 10.1210/jcem-67-3-493. [DOI] [PubMed] [Google Scholar]
  2. BAYLEY N., PINNEAU S. R. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952 Apr;40(4):423–441. doi: 10.1016/s0022-3476(52)80205-7. [DOI] [PubMed] [Google Scholar]
  3. Blum W. F., Ranke M. B., Kietzmann K., Gauggel E., Zeisel H. J., Bierich J. R. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab. 1990 May;70(5):1292–1298. doi: 10.1210/jcem-70-5-1292. [DOI] [PubMed] [Google Scholar]
  4. Carlsson L. M., Rowland A. M., Clark R. G., Gesundheit N., Wong W. L. Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood. J Clin Endocrinol Metab. 1991 Dec;73(6):1216–1223. doi: 10.1210/jcem-73-6-1216. [DOI] [PubMed] [Google Scholar]
  5. De Schepper J., Craen M., Massa G., Heinrichs C., Maes M., Du Caju M., Rausin L., Bourguignon J. P. Growth hormone therapy in Turner's syndrome: one versus two daily injections. J Clin Endocrinol Metab. 1994 Aug;79(2):489–494. doi: 10.1210/jcem.79.2.8045968. [DOI] [PubMed] [Google Scholar]
  6. Haeusler G., Schmitt K., Blümel P., Plöchl E., Waldhör T., Frisch H. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height. Acta Paediatr. 1996 Dec;85(12):1408–1414. [PubMed] [Google Scholar]
  7. Hokken-Koelega A. C., Hackeng W. H., Stijnen T., Wit J. M., de Muinck Keizer-Schrama S. M., Drop S. L. Twenty-four-hour plasma growth hormone (GH) profiles, urinary GH excretion, and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal insufficiency and severe growth retardation. J Clin Endocrinol Metab. 1990 Sep;71(3):688–695. doi: 10.1210/jcem-71-3-688. [DOI] [PubMed] [Google Scholar]
  8. Kamp G. A., Kuilboer M. M., Wynne H. J., Rongen-Westerlaken C., Johnson M. L., Veldhuis J. D., Wit J. M. Slow baseline growth and a good response to growth hormone (GH) therapy are related to elevated spontaneous GH pulse frequency in girls with Turner's syndrome. J Clin Endocrinol Metab. 1993 Jun;76(6):1604–1609. doi: 10.1210/jcem.76.6.8501169. [DOI] [PubMed] [Google Scholar]
  9. Kratzsch J., Blum W. F., Ventz M., Selisko T., Birkenmeyer G., Keller E. Growth hormone-binding protein-related immunoreactivity in the serum of patients with acromegaly is regulated inversely by growth hormone concentration. Eur J Endocrinol. 1995 Mar;132(3):306–312. doi: 10.1530/eje.0.1320306. [DOI] [PubMed] [Google Scholar]
  10. Lanes R., Brito S., Suniaga M., Moncada G., Borges M. Growth hormone secretion in pubertal age patients with Turner's syndrome. J Clin Endocrinol Metab. 1990 Sep;71(3):770–772. doi: 10.1210/jcem-71-3-770. [DOI] [PubMed] [Google Scholar]
  11. Lenko H. L. Prediction of adult height with various methods in Finnish children. Acta Paediatr Scand. 1979 Jan;68(1):85–92. doi: 10.1111/j.1651-2227.1979.tb04965.x. [DOI] [PubMed] [Google Scholar]
  12. Lyon A. J., Preece M. A., Grant D. B. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985 Oct;60(10):932–935. doi: 10.1136/adc.60.10.932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Massa G., Maes M., Heinrichs C., Vandeweghe M., Craen M., Vanderschueren-Lodeweyckx M. Influence of spontaneous or induced puberty on the growth promoting effect of treatment with growth hormone in girls with Turner's syndrome. Clin Endocrinol (Oxf) 1993 Mar;38(3):253–260. doi: 10.1111/j.1365-2265.1993.tb01003.x. [DOI] [PubMed] [Google Scholar]
  14. Massa G., Otten B. J., de Muinck Keizer-Schrama S. M., Delemarre-van de Waal H. A., Jansen M., Vulsma T., Oostdijk W., Waelkens J. J., Wit J. M. Treatment with two growth hormone regimens in girls with Turner syndrome: final height results. Dutch Growth Hormone Working Group. Horm Res. 1995;43(4):144–146. doi: 10.1159/000184262. [DOI] [PubMed] [Google Scholar]
  15. Nienhuis H. E., Rongen-Westerlaken C., Wit J. M., Otten B. J., de Muinck Keizer-Schrama S. M., Drayer N. M., Delemarre-van de Waal H. A., Vulsma T., Oostdijk W., Waelkens J. J. Results of long-term therapy with growth hormone in two dose regimens in Turner syndrome. Dutch Growth Hormone Working Group. Horm Res. 1993;39 (Suppl 2):31–36. doi: 10.1159/000182765. [DOI] [PubMed] [Google Scholar]
  16. Nilsson K. O., Albertsson-Wikland K., Alm J., Aronson S., Gustafsson J., Hagenäs L., Häger A., Ivarsson S. A., Karlberg J., Kriström B. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. J Clin Endocrinol Metab. 1996 Feb;81(2):635–640. doi: 10.1210/jcem.81.2.8636281. [DOI] [PubMed] [Google Scholar]
  17. Ranke M. B., Blum W. F., Haug F., Rosendahl W., Attanasio A., Enders H., Gupta D., Bierich J. R. Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinol (Copenh) 1987 Nov;116(3):305–313. doi: 10.1530/acta.0.1160305. [DOI] [PubMed] [Google Scholar]
  18. Ranke M. B., Pflüger H., Rosendahl W., Stubbe P., Enders H., Bierich J. R., Majewski F. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr. 1983 Dec;141(2):81–88. doi: 10.1007/BF00496795. [DOI] [PubMed] [Google Scholar]
  19. Rosenfeld R. G., Frane J., Attie K. M., Brasel J. A., Burstein S., Cara J. F., Chernausek S., Gotlin R. W., Kuntze J., Lippe B. M. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr. 1992 Jul;121(1):49–55. doi: 10.1016/s0022-3476(05)82540-5. [DOI] [PubMed] [Google Scholar]
  20. Ross J. L., Long L. M., Loriaux D. L., Cutler G. B., Jr Growth hormone secretory dynamics in Turner syndrome. J Pediatr. 1985 Feb;106(2):202–206. doi: 10.1016/s0022-3476(85)80287-0. [DOI] [PubMed] [Google Scholar]
  21. Smith P. J., Hindmarsh P. C., Brook C. G. Contribution of dose and frequency of administration to the therapeutic effect of growth hormone. Arch Dis Child. 1988 May;63(5):491–494. doi: 10.1136/adc.63.5.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Taback S. P., Collu R., Deal C. L., Guyda H. J., Salisbury S., Dean H. J., Van Vliet G. Does growth-hormone supplementation affect adult height in Turner's syndrome? Lancet. 1996 Jul 6;348(9019):25–27. doi: 10.1016/s0140-6736(96)01267-6. [DOI] [PubMed] [Google Scholar]
  23. Underwood L. E. The social cost of being short: societal perceptions and biases. Acta Paediatr Scand Suppl. 1991;377:3–8. doi: 10.1111/apa.1991.80.s377.3. [DOI] [PubMed] [Google Scholar]
  24. Van den Broeck J., Massa G. G., Attanasio A., Matranga A., Chaussain J. L., Price D. A., Aarskog D., Wit J. M. Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. J Pediatr. 1995 Nov;127(5):729–735. doi: 10.1016/s0022-3476(95)70161-3. [DOI] [PubMed] [Google Scholar]
  25. Wit J. M., Massarano A. A., Kamp G. A., Hindmarsh P. C., van Es A., Brook C. G., Preece M. A., Matthews D. R. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol (Copenh) 1992 Jul;127(1):7–12. doi: 10.1530/acta.0.1270007. [DOI] [PubMed] [Google Scholar]
  26. van Teunenbroek A., Stijnen T., Otten B., de Muinck Keizer-Schrama S., Naeraa R. W., Rongen-Westerlaken C., Drop S. A regression method including chronological and bone age for predicting final height in Turner's syndrome, with a comparison of existing methods. Acta Paediatr. 1996 Apr;85(4):413–420. doi: 10.1111/j.1651-2227.1996.tb14052.x. [DOI] [PubMed] [Google Scholar]
  27. van Teunenbroek A., de Muinck Keizer-Schrama S. M., Stijnen T., Jansen M., Otten B. J., Delemarre-van de Waal H. A., Vulsma T., Wit J. M., Rouwé C. W., Reeser H. M. Yearly stepwise increments of the growth hormone dose results in a better growth response after four years in girls with Turner syndrome. Dutch Working Group on Growth Hormone. J Clin Endocrinol Metab. 1996 Nov;81(11):4013–4021. doi: 10.1210/jcem.81.11.8923853. [DOI] [PubMed] [Google Scholar]
  28. van Teunenbroek A., de Muinck Keizer-Schrama S. M., Stijnen T., Mouton J. W., Blum W. F., Mercado M., Baumann G., Drop S. L. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone. Clin Endocrinol (Oxf) 1993 Jul;39(1):77–84. doi: 10.1111/j.1365-2265.1993.tb01754.x. [DOI] [PubMed] [Google Scholar]
  29. van Teunenbroek A., de Muinck Keizer-Schrama S., Stijnen T., Waelkens J., Wit J. M., Vulsma T., Gerver W. J., Reeser H., Delemarre-van de Waal H., Jansen M. Growth response and levels of growth factors after two years growth hormone treatment are similar for a once and twice daily injection regimen in girls with Turner syndrome. (Dutch Working Group on Growth Hormone). Clin Endocrinol (Oxf) 1997 Apr;46(4):451–459. doi: 10.1046/j.1365-2265.1997.1610972.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES